Insulin sensitivity following treatment with the α1-blocker bunazosin retard and the α1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients

Journal of Hypertension

Volumn 14, Issue 12, 1996, Pages 1469-1475

  Eriksson, Jan W ^a,b   Jansson, Per Anders ^a   Foley, Karen ^c   Lithell, Hans ^d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c EISAI CO LTD   (Japan)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Euglycaemic clamp; Hypertension; Insulin resistance; Non insulin dependent diabetes mellitus; 1 blockade; 1 blockade

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN; FIBRINOGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNILOC;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; EPISTAXIS; FIBRINOGEN BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030444763     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199612000-00014     Document Type: Article

References (22)

1. Shoji T: Comparison of pre- and post-synaptic α-adrenoceptor blocking effects of E-643 in the isolated vas deferens of the rat. Jpn J Pharmacol 1981, 31:361-368.
2. Igarashi T, Nakajima Y, Ohtake S: Comparison of effects of α-blocking agentson blood pressure and heart rate in unanesthetized spontaneously hypertensive (SHR) and normotensive rats. Clin Exp Pharmacol Physiol 1976, 3 (suppl):89-92.
3. Sakanashi M, Noguchi K, Kato T, Miyamoto Y, Nakasone J, Takeo S: Acute effects of bunazosin on aortic, vertebral, coronary and renal blood flows of anesthetized dogs. Arzneimittelforschung 1986, 36:1202-1205.
4. Kawasaki T, Uezono K, Abe I, Nakamuta S, Ueno M, Kawazoe N, et al.: Antihypertensive effect of E-643, a new α-adrenergic blocking agent. Eur J Clin Pharmacol 1981, 20:339-405.
5. 1-blocker (bunazosin). Am J Hypertens 1992, 5:969-874.
6. 1-blocker, on plasma lipids in diabetic subjects with essential hypertension. Curr Ther Res 1989, 45:677-683
7. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
8. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14: 173-194.
9. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä, K, Salonen JT, et al.: Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991, 11:1068-1076
10. Inchiostro S, Bertoli, G, Zanette G, Donadon V: Evidence of higher insulin resistance in NIDDM patients with ischaemic heart disease. Diabetologia 1994, 37:597-603.
11. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415-420.
12. Uusitupa MIJ, Niskanen LK, Sutonen O, Voutainen E, Pyörälä K: 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990, 82:27-36.
13. De Fronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:214-233.
14. Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989, 298:1152-1157.
15. Lithell H, Pollare T, Berne C: Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990, 15 (suppl 5):546-552.
16. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868-873.
17. Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 1992, 41: 1076-1083.
18. Schiffrin EL, Deng LY, Larochelle P: Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a β-blocker. Am J Hypertens 1995, 8: 229-236.
19. Beck-Nielsen H, Groop LC: Metabolic and genetic characterization of prediabetic states. J Clin Invest 1994, 94:1714-1721.
20. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Ward R, Alessi MC, et al.: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986, 35:250-263.
21. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993, 137:959-965.
22. Robertson RP, Porte D: Adrenergic modulation of basal insulin secretion in man. Diabetes 1973, 22:1-8.